A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

Despite the diverse nature of obesity, there is compelling genetic, clinical, and experimental evidence that endorses the ...

After Novo Nordisk and Eli Lilly transformed the market for obesity treatment, a flood of drugmakers has ... Metsera is ...

Ilant Health, a leading provider of value-based obesity and cardiometabolic health solutions, today announced that Galway ...

COPENHAGEN (Reuters) -Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance ...

Subscribe for FREE GLP-1s, used to treat obesity, diabetes and heart problems, delay gastric emptying, and residual food or liquid in the stomach at the time of surgery with general anesthesia, may ...

"it will be important to obtain data on whether semaglutide is similarly effective in persons with osteoarthritis without obesity, as well as better data on whether GLP-1 receptor agonists prevent ...

which reimagines obesity treatment with a mechanism that directly impacts fat cells – particularly visceral fat – and which could be used as monotherapy, add-on to GLP-1s, or for maintenance p ...

The family of weight-loss jabs known as GLP-1 agonists are among pharma’s biggest blockbusters. But drugs like Ozempic have the potential to do much more than tackle diabetes and obesity.

There was a 132.6 percent increase in patients prescribed GLP-1 RAs between the last six months of 2022 and the last six ...

The firm said GLP-1 drugs for obesity account for about 10% of all pharmacy spending. Those cost concerns haven't abated. Most companies still don't cover GLP-1 prescriptions for weight loss ...